News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

14th Apr 21

Pharmaxis Sells Bronchitol Russian Distribution Rights for A$2m with Annual A$1m Cost Savings

Highlights:

  • Pharmaxis sells distribution rights for Bronchitol in Russia effective May 1st 2021
  • Pharmaxis to receive a €1.25 million (~A$2m) distributor appointment fee
  • Annual cost savings of approximately A$1m realised from transfer of commercial and product responsibilities
Read full media release - pdf
14th Apr 21

Pharmaxis Announces A$4.4m Placement

Highlights:

  • A$4.4m being raised in a placement to institutional investors
  • A$20m pro-forma cash balance post raising  
  • Strengthened balance sheet to support ongoing clinical studies in myelofibrosis and skin scarring  
  • Issue price of A$0.08 represents a 1.3% premium to last closing price as at 12 April 2021
  • New shareholder Karst Peak Capital Limited invests A$3.2m for a 8.9% holding in the Company
  • Existing shareholder BVF Partners LP invests A$0.8m to maintain its holding at 19.5%
Read full media release - pdf
31st Mar 21

Pharmaxis Announces World First Clinical Trial of Treatment to Prevent Wound and Burns Scars

A Pharmaxis (ASX:PXS) drug discovery has entered a world first clinical trial aiming to stop scars forming after trauma, particularly following burn injuries. Distinguished surgeon and burns expert Professor Fiona Wood AM is leading a group of researchers from the University of Western Australia (UWA) and Fiona Stanley Hospital to test the treatment in the first human trials. Skin scarring after events such as accidents, surgery or burns place a substantial physical and psychological burden on patients. 

Professor Fiona Wood said, “It’s exciting for the research team to explore a novel path to reduce scarring and to be moving closer to that goal. Scar-less healing is the vision that has motivated our work over many decades.”

The Pharmaxis discovery, known as PXS-6302, has shown promising pre-clinical results in inhibiting the enzymes that play a critical role in the development of scar tissue.

Dr Kylie Sandy-Hodgetts, Senior Research Fellow at the School of Biomedical Sciences, UWA, said, “Current treatments aim to rectify the scar in the acute phase such as during wound healing and scar maturation through options such as compression therapy, silicone gel sheeting or when the scar is established by cryotherapy, scar revision or laser with limited outcomes at times.”

“This new compound may potentially avoid the need for invasive procedures such as further surgery or laser procedures.”

 The world-first human trial will determine the safety and tolerability of the product in healthy volunteers, which will lead to further trials in burns and surgical patients.

Read full media release - pdf